Fortress Biotech, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, FL, 33154
Mailing Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, FL, 33154
Phone
781-652-4500
Fiscal Year End
1231
EIN
205157386
Financial Overview
FY2025
$6.82M
Net Income
$-0.07
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 8-K Current report of material events | February 23, 2026 | View on SEC |
| 8-K Current report of material events | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Operates a diversified venture capital-style model for drug development through specialized subsidiaries.
- Strong commercial focus on dermatology through Journey Medical Corporation, driven by Qbrexza and Emrosi.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.